Biomedicine & Pharmacotherapy 91 (2017) 546–558

Available online at
ScienceDirect
www.sciencedirect.com

Elsevier Masson France
EM|consulte
www.em-consulte.com/en

Review

New drugs for the treatment of *Mycobacterium tuberculosis* infection

Manaf AlMatar[a,*], Husam AlMandeal[b], Işıl Var[c], Begüm Kayar[d], Fatih Köksal[d]

[a] Department of Biotechnology, Institute of Natural and Applied Sciences (Fen Bilimleri Enstitüsü), Cukurova University, Adana, Turkey
[b] Universitätsklinikum des Saarlandes, Gebäude 90, Kirrberger Straße, D-66421, Homburg, Germany
[c] Department of Food Engineering, Agricultural Faculty, Cukurova University, Adana, Turkey
[d] Department of Medical Microbiology, Faculty of Medicine, Çukurova University, Adana, Turkey

ARTICLE INFO

Article history:
Received 18 February 2017
Received in revised form 29 March 2017
Accepted 23 April 2017

Keywords:
Tuberculosis
Antitubercular agents
Novel drugs
Antibiotic
Clinical trials
Mode of action

ABSTRACT

Tuberculosis presents a grave challenge to health, globally instigating 1.5 million mortalities each year. Following the breakthrough of first-line anti-TB medication, the number of mortalities reduced greatly; nonetheless, the swift appearance of tuberculosis which was drug-resistant, as well as the capability of the bacterium to survive and stay dormant are a considerable problem for public health. In order to address this issue, several novel possible candidates for tuberculosis therapy have been subjected to clinical trials of late. The novel antimycobacterial agents are acquired from different categories of medications, operate through a range of action systems, and are at various phases of advancement. We therefore talk about the present methods of treating tuberculosis and novel anti-TB agents with their action method, in order to advance awareness of these new compounds and medications.

Contents

1. Introduction

Tuberculosis (TB) consists of one of mankind's widespread, infectious and deadly diseases. Every year, millions of new instances are discovered globally, and thirty percent of the global

* Corresponding author.
E-mail addresses: manafmatar19@gmail.com, manafmatar1985@gmail.com (M. AlMatar).

http://dx.doi.org/10.1016/j.biopha.2017.04.105
0753-3322/

populace has potential TB infection. Tuberculosis is triggered by mycobacteria, specifically *Mycobacterium tuberculosis* (MTB) [1]. The approximation by WHO in 2015 was 10.4 million instances of TB (ranging from 8.7 million to 12.2 million), equalling 142 instances for every 100,000 people. An approximate 1.4 million mortalities (ranging from 1.2 million to 1.6 million) caused by TB were documented amid HIV-negative individuals during 2015, with a further 0.39 million mortalities (ranging from 1.2 million to 1.6 million) caused by TB amid HIV-negative individuals. TB consists of one of the 10 prevalent causes of mortality globally, and instigated more mortalities compared to HIV/AIDS during 2015. Within 2015, an approximated 480,000 new incidences of multidrug-resistant TB (MDR-TB), with a further 100,000 individuals having rifampicin-resistant TB (RR-TB) that were additionally recently qualified for MDR-TB therapy. MDR/RR-TB resulted in 250,000 deaths during 2015. The majority of instances and deaths happened in Asia. A mere 52% of the MDR/RR-TB treatment individuals who commenced therapy during 2013 were treated successfully, with 17% dying and 9% experiencing treatment failure (22% did not undergo appraisal or follow-up). The level of treatment success for XDR-TB patients was just 26% [2]. The 2015 yearly tuberculosis report from WHO declares that "in the absence of new tuberculosis medications and regimens, enhancement of treatment results in the near future will be a challenge," stating "augmented research and development consists of one of the three tenets of the Post-2015 Global Tuberculosis Strategy by WHO, and will have an essential function in speeding up the decreases in tuberculosis occurrence and death necessary for achieving international tuberculosis targets before 2035 [3]. A considerable achievement within TB control during the previous 15 years has consisted on the advancement of novel antimycobacterial medication. These novel agents offer optimism that imminent treatment regimens for drug-resistant TB may be additionally competent, and more successful than the present regimens [4]. Within this context of great need to new TB agents, this review provides an overview of these new agents, including descriptions of their mechanisms of action, evidence for their efficacy and safety, and highlights of their pending investigations

2. Current treatment methods

Anti-TB therapy intends to avoid complications and mortality, cure the individual, prevent recurrences decrease the possible conveyance to sensitive individuals, and restrict the appearance and dissemination of strains that are drug-resistant. To meet all these requirements, the treatment method for TB necessitates the employment of several medications. Therapy has to encompass a comprehensive stage intended to noticeably reduce the bacterial burden, succeeded by a sterilising stage of consolidation, with a general period of a minimum of six months. More extended therapies could be necessary in specific circumstances, like for patients having considerable bone inclusion or those encountering cerebral tuberculomas [5]. Tuberculosis diagnosis has experienced swift development during the previous ten years. Even though culture is still the standard for diagnosis as well as drug-sensitivity assessment, molecular diagnostics with DNA basis have become broadly accessible and allow swift diagnosis in addition to primary appraisal of drug sensitivity. Such methods enable swift commencement of TB treatment regimens which may be anticipated to be efficient for singular patients. Preferably, the primary isolate for every patient has to be appraised to rule out basic drug resistance; if there are inadequate resources, this assessment should be carried out at least for all individuals who have had prior TB treatment or interaction with an individual having drug-resistant isolates. The regular treatment regimen for apparent drug-sensitive tuberculosis encompasses an induction stage comprised of isoniazid, rifampin and pyrazinamide, in which ethambutol is encompassed as a safeguard towards unidentified resistance of one of three main medications. As soon as sensitivity to pyrazinamide, rifampin and isoniazid is verified, ethambutol may be stopped. For younger children, this medication is regularly excluded if the origin of infection is known as having drug sensitivity to tuberculosis, as identifying the poisonous impact of ethambutol is difficult within children. The induction stage is succeeded by a consolidation stage comprised of isoniazid and rifampin over an extra four months of therapy. The regular 6-month treatment regimen for drug-sensitive tuberculosis is a particularly extended treatment regimen in contrast to the period of therapy for alternative bacterial infectious illnesses [6,7]. The extended regimen presents two key problems for success: controlling drug noxiousness and ascertaining that patients observe the entire treatment course. Drug toxicity is considerable; an appraisal of retrospective studies employing comparable definitions approximates that 3 to 13 percent of individuals have hepatoxic influence [8]. A current potential cohort study of patients having drug-sensitive disease who attained regular tuberculosis treatment recorded a 15% occurrence of negative medication responses causing disturbance or stoppage of one or several medications [9]. From these negative responses, 7.7% caused hospitalization, mortality or disability. A broad range of responses were documented; the most widespread consisted of hepatoxic influences, gastrointestinal disorders, in addition to arthralgias and allergic responses. In general, 16 to 49% of patients do not finish the treatment [10]. Causes for incapability to conclude therapy are broad and encompass negative drug responses, expense of treatment, stigma, and the certainty of the patient that cure has been attained if the symptoms have subsided and bacteria is not available in the sputum [11]. Treatment support in addition to direct-observation regimens are practical in enhancing observation, but have not totally addressed these elements. There is insufficient proof to sustain therapy suggestions for drug-sensitive illness [12].

Even though the therapy success level of drug-sensitive TB surpasses 85% at an international extent even within elevated-burden contexts, the result is considerably inferior for patients who have drug-resistant TB (50% on average) [13]. MDR-TB is described as resistance to at least isoniazid and rifampicin, while XDR-TB encompasses MDR-TB instances with extra resistance to any fluoroquinolone and any of the injectable medications. The therapy results are reduced in instances of XDR-TB (40% on average), although they could be as little as 19% of the illness is maintained by strains of MD with a resistance sequence above XDR [14,15]. The primary treatment regimen has to be singularly specified in line with the outcomes of drug-sensitivity assessment of the *M. tuberculosis* isolate from the individual, with assessment carried out either through culture or by the employment of DNA-founded techniques. In the lack of this information, empirical treatments may be employed, although immediately when the outcomes from drug sensitivity assessment are accessible, the treatment regimen has to be altered [16]. Using a massive *meta*-analysis as a base, the WHO suggests that the primary regimen for treating MDR tuberculosis encompass four medications towards which the isolate of the individual is sensitive (as well as pyrazinamide, for which sensitivity outcomes are not always accessible) within the induction stage, which has to extend 6 to 8 months [17]. A number of observational researches have proposed that an induction stage with additional medications towards which the individual's isolate is sensitive is related to enhanced results [18–20]. The requirement to employ more medications possibly mirrors the inferior antimycobcterial action of these medications in contrast to isoniazid, rifampin as well as pyrazinamide. Furthermore, these medications are considerably more poisonous compared to those employed in the therapy of drug-sensitive